NIOX GROUP PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.6 GBX | +0.57% |
|
+0.86% | +5.37% |
| 05-22 | EARNINGS AND TRADING: Adnams toasts increase in sales but loss widens | AN |
| 04-04 | NIOX Group Plc Proposes Final Dividend for the Financial Year Ended 31 December 2023, Payable on 24 June 2024 | CI |
| Sales 2024 * | 42.38M 53.99M 4.24B | Sales 2025 * | 47.73M 60.81M 4.77B | Capitalization | 299M 381M 29.94B |
|---|---|---|---|---|---|
| Net income 2024 * | 12M 15.29M 1.2B | Net income 2025 * | 14M 17.84M 1.4B | EV / Sales 2024 * | 6.41 x |
| Net cash position 2024 * | 27.82M 35.45M 2.78B | Net cash position 2025 * | 36.49M 46.49M 3.65B | EV / Sales 2025 * | 5.51 x |
| P/E ratio 2024 * |
25.7
x | P/E ratio 2025 * |
22
x | Employees | 92 |
| Yield 2024 * |
1.57% | Yield 2025 * |
2.08% | Free-Float | 50.26% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.57% | ||
| 1 week | +0.86% | ||
| 1 month | -0.56% | ||
| 3 months | +13.14% | ||
| 6 months | +11.36% | ||
| Current year | +5.37% |
1 week
69.48
74.00
1 month
68.6875.60
Current year
57.2075.60
1 year
54.0075.60
3 years
27.8675.60
5 years
12.5075.60
10 years
12.50356.00
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Roller
DFI | Director of Finance/CFO | 59 | 08/01/20 |
Jan Lundquist
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jonathan Emms
COO | Chief Operating Officer | - | 01/09/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Johnson
CHM | Chairman | 71 | 04/12/19 |
Michael Roller
DFI | Director of Finance/CFO | 59 | 08/01/20 |
Garry Watts
BRD | Director/Board Member | 67 | 01/03/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 70.6 | +0.57% | 673,679 |
| 30/05/24 | 70.2 | -2.50% | 70,469 |
| 29/05/24 | 72 | +2.27% | 1,487,081 |
| 28/05/24 | 70.4 | +0.57% | 120,587 |
| 24/05/24 | 70 | -1.96% | 7,737,927 |
Delayed Quote London S.E., May 31, 2024 at 04:35 pm
More quotes
NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
Sector
Pharmaceuticals
Calendar
24/09/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.706
GBP
Average target price
0.7825
GBP
Spread / Average Target
+10.84%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.37% | 381M | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- CIR Stock
